 ENGLEWOOD, Colo., June 15, 2021 PRNewswire -- Ampio Pharmaceuticals NYSE American: AMPE, a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced it has received regulatory approval to expand enrollment of its AP-019 Phase II study to India. 